Darren Geliga, PA
Medical · Kailua Kona, HINPI 1508804584
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 362 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 14.2% — the pattern of someone who eats at a lot of different presentations. Among medical clinicians in HI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 362 payments — averaging $22.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Lilly USA, LLC$1K
- AbbVie$871
- Amarin Pharma, Inc.$647
- Bayer$582
- Johnson & Johnson$461
- plus $3K from 24 others
What the payments were for
- Food & beverage$8,207100%
- Education$150%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 60 | $1,164 |
| Lilly USA, LLC | 47 | $1,046 |
| AbbVie | 36 | $871 |
| Amarin Pharma, Inc. | 26 | $647 |
| Bayer | 23 | $582 |
| Johnson & Johnson(2 entities) | 32 | $461 |
| Takeda Pharmaceuticals U.S.A., Inc. | 31 | $454 |
| Amgen | 17 | $362 |
| Pfizer | 17 | $343 |
| Abiomed | 5 | $343 |
| AstraZeneca | 13 | $271 |
| Merck | 11 | $270 |
| Boehringer Ingelheim | 10 | $213 |
| Esperion Therapeutics, Inc. | 8 | $189 |
| Sanofi-aventis U.S. LLC | 2 | $166 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $138 |
| Sanofi | 1 | $130 |
| Janssen Scientific Affairs, LLC | 1 | $94 |
| Lundbeck LLC | 4 | $89 |
| Gilead | 3 | $74 |
| Insmed, Inc. | 3 | $59 |
| Vanda Pharmaceuticals Inc. | 2 | $55 |
| Dexcom, Inc. | 1 | $29 |
| GSK | 1 | $29 |
| Myriad Genetic Laboratories, Inc. | 1 | $28 |
| Baxter Healthcare | 1 | $25 |
| Otsuka America Pharmaceutical, Inc. | 1 | $25 |
| Axsome Therapeutics, Inc. | 1 | $23 |
| Exact Sciences | 1 | $21 |
| Novartis | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,221 in reported general payments places this provider in the 90th percentile of 63 medical providers in Hawaii.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 51 | $78,303 |
| TrulicityDulaglutide | 33 | $46,128 |
| XareltoRivaroxaban | 28 | $37,978 |
| TrintellixVortioxetine Hydrobromide | 41 | $34,432 |
| MounjaroTirzepatide | 29 | $34,158 |
| EliquisApixaban | 19 | $30,345 |
| JardianceEmpagliflozin | 19 | $26,154 |
| VascepaIcosapent Ethyl | 18 | $12,432 |
| ProgesteroneProgesterone, Micronized | 99 | $7,670 |
| FarxigaDapagliflozin Propanediol | 11 | $7,579 |
| Repatha SureclickEvolocumab | 11 | $7,454 |
| Testosterone Cypionate | 95 | $6,882 |
| Liothyronine Sodium | 93 | $4,903 |
| Testosterone | 14 | $3,994 |
| Rosuvastatin Calcium | 79 | $3,799 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $1,046 | $80,28662 claims |
| Novo NordiskOzempic | $1,164 | $78,30351 claims |
| Johnson & JohnsonXarelto | $461 | $37,97828 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $454 | $34,43241 claims |
| PfizerEliquis | $343 | $30,34519 claims |
| Boehringer IngelheimJardiance | $213 | $26,15419 claims |
| AstraZenecaFarxiga | $271 | $7,57911 claims |
| AbbVieSynthroid | $871 | $1,80831 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 63 medical providers in Hawaii.
Other medical in Kailua Kona
- Natalie HammondKailua Kona$853
- Athena ZechaKailua Kona$357
- Kellie AcostaKailua Kona$34
- Akane DunnKailua Kona$33
- Dianna GuentherKailua Kona$29
- Lisa AdamsHonolulu$189K
- Susan StewartWailuku$47K
- Leena HongHonolulu$30K
- Jeanelle AhunaHonolulu$16K
- Justin MaioHonolulu$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.